Bone remodelling is a continuous process by which bone resorption by osteoclasts is followed by bone formation by osteoblasts to maintain skeletal homeostasis. These two forces must be tightly coordinated not only quantitatively, but also in time and space, and its malfunction leads to diseases such as osteoporosis. Recent research focusing on the cross-talk and coupling mechanisms associated with the sequential recruitment of osteoblasts to areas where osteoclasts have removed bone matrix have identified a number of osteogenic factors produced by the osteoclasts themselves. Osteoclast-derived factors and exosomal-containing microRNA (miRNA) can either enhance or inhibit osteoblast differentiation through paracrine and juxtacrine mechanisms, and therefore may have a central coupling role in bone formation. Entwined with angiocrine factors released by vessel-specific endothelial cells and perivascular cells or pericytes, these factors play a critical role in angiogenesis-osteogenesis coupling essential in bone remodelling.
I. Introduction .............................................................................................. 470 II. The bone remodelling unit and cycle ..................................................................... 470 (1) Initiation phase ....................................................................................... 470 (2) ......................................................... 476 V. Conclusions .............................................................................................. 478 VI. Acknowledgements ....................................................................................... 478 VII. References ................................................................................................ 478 
I. INTRODUCTION
The skeleton is a metabolically active organ that undergoes constant remodelling throughout life to maintain its structural integrity and calcium homeostasis. Bone remodelling relies on the accurate balance between bone resorption by osteoclasts and bone matrix formation by mesenchymal lineage osteoblasts, and involves a complex series of sequential steps that are highly regulated. The group of cells actively participating in remodelling are collectively designated the 'basic multicellular unit' (BMU) (Kular et al., 2012; Sims & Walsh, 2012) . The cellular activities in each BMU aim to achieve a correct balance between osteoblast and osteoclast activity in response to osteoclastic bone resorption, designated 'coupling', to maintain a balanced bone mass. Evidence indicates that the growth of blood vessels and activity of vascular endothelial growth factor (VEGF) in bone and osteogenesis are also coupled, and this coupling is regulated by different capillary subtypes (Clarkin & Gerstenfeld, 2013; . The recruitment of osteoprogenitors from the canopy onto reversal surfaces is also important during bone remodelling (Jensen et al., 2015) . When this coupling is interrupted, the accurate bone mass is compromised, leading to skeletal disorders such as osteoporosis and osteopetrosis. A greater understanding of the mechanisms underlying the coordination of coupling between osteoclasts and osteoblasts in bone remodelling may open a new avenue to identifying target molecules for alternative therapies more efficacious against these bone disorders.
This review aims to provide an exploration of coupling factors and mechanism of cross-talks between the osteoclasts and osteoblasts, and to relate their functionality to uncoupling consequences in pathological bone and joint diseases. The regulatory mechanisms of osteoblast-directed osteoclastic bone resorption are well documented, however there is accumulating evidence to indicate that osteoclasts conversely have a part in the control of osteoblastic bone formation. Dissecting the molecular mechanisms that regulate the function of coupling factors in bone remodelling will give an insight into the direction of potential future therapies for bone diseases.
II. THE BONE REMODELLING UNIT AND CYCLE
Bone remodelling takes place within anatomically distinct sites within the skeleton termed the basic multicellular unit (BMU), which comprises a tightly regulated cohort of cells (Kular et al., 2012; Sims & Walsh, 2012) (Fig. 1) . During this process unwanted or damaged bone is resorbed by osteoclasts and replaced with new bone by osteoblasts at approximately the same location, to maintain bone mass at the same level during adult life. It is distinct as well from bone modelling where bone formation occurs at sites that have not been affected by osteoclastic resorption, resulting in transformation of the size, shape, and/or micro-architecture of bone. It should be noted that the concept that osteocyte-directed bone remodelling is always damage-driven may not be completely correct, and multiple factors play a role in the remodelling process (Currey, Dean & Shahar, 2016) .
Bone remodelling is a multicellular event involving osteoprogenitors on the bone surface, capillary blood vessels, mesenchymal envelope-like canopy cells surrounding the bone marrow, osetocytes and the bone matrix itself (Fig. 1) . These multiple cell types communicate or engage in cross-talk with one another, and are essential for proper bone development and homeostasis (Schipani et al., 2013) . In general, the bone remodelling cycle is accomplished in three distinct sequential phases (Fig. 2) : the initiation phase, reversal phase, and termination phase.
(1) Initiation phase
During the initiation phase, there is recruitment of osteoclast precursors to the BMU from hematopoietic precursors, and differentiation of osteoclast precursors into multinucleated osteoclasts. Control of osteoclast differentiation and activation is regulated by osteoblast-expressed molecules such as receptor activator of nuclear factor kappa-B ligand (RANKL), osteoprotegerin (OPG) (Sims & Martin, 2014 , and Semaphorin 3A (Sema-3A) (Hayashi et al., 2012) .
(2) Reversal phase
A reversal phase then emerges whereby osteoclast function is subdued via apoptosis and/or autophagy, whereas osteoblast lineage cells are recruited and differentiated. The transition from osteoclast bone resorption to osteoblast bone formation occurs in the reversal phase. There appears to be a gap in this transition period between bone resorption and formation (Sims & Martin, 2014 , and coupling mechanisms are employed to overcome this delay (Fig. 2) . Osteoclast-derived factors can directly or indirectly (being refined by other factors) initiate the differentiation of osteoblasts in resorbed sites to form new bone. Other anabolic coupling factors are also released from the resorbed bone matrix and other cell types within the BMU [e.g. transforming growth factor ß (TGF-ß)], and bidirectional signalling between EphrinB2 on osteoclasts and EphrinB4 on osteoblast precursors might facilitate this transition phase.
(3) Termination phase
The termination phase involves osteoblastic bone formation and mineralization of the bone matrix (Raggatt & Partridge, 2010) . The estimated average length of the remodelling phase in human cancellous bone from the iliac crest is approximately 3 weeks for bone resorption, 3-4 months for bone formation (Eriksen et al., 1984a; Eriksen, Melsen & Mosekilde, 1984b) , and 5 weeks for the reversal phase (Tran Van, Vignery & Baron, 1982) . However, the period of the bone remodelling process varies by species and type of bone, and is influenced by disruption or perturbation of coupling activities in pathological conditions such as osteoporosis, bone tumours, rheumatoid arthritis, and osteoarthritis.
III. OSTEOCLAST-DERIVED COUPLING FACTORS
The concept of 'coupling' in the bone remodelling process was first proposed by Frost's group who observed that sites of osteoclastic bone resorption were sequentially replaced by osteoblastic bone formation (Hattner, Epker & Frost, 1965) . It is thought that during osteoclastic bone resorption, coupling factors are produced by osteoclasts to regulate osteoblast activity in the BMU (Table 1) . To date, four major classes of osteoclast-derived coupling factors have been reported which include osteoclast-secreted factors, matrix-derived factors released during osteoclastic bone resorption, osteoclast membrane-bound molecules, and osteoclast-derived exosomal microRNAs (miRNAs) (Fig. 3) .
(1) Osteoclast-secreted factors: a paracrine mechanism A number of factors are produced by osteoclasts, which via a paracrine mode of action, promote osteoblast migration, differentiation, and bone formation in the BMU (Fig. 3A) . The increase in bone formation (due to an increased number of osteoclasts) observed with the impairment of bone resorption due to a deficiency of the chloride channel ClC-7 or proto-oncogene tyrosine-protein kinase Src (c-src) activity (Marzia et al., 2000; Schaller et al., 2004) , suggests that osteoclasts exhibit coupling mechanisms that promote osteoblast activity independently of their bone-resorbing activity. A number of these osteoclast-secreted factors act as a ligand and bind to their receptors on pre-osteoblasts to facilitate the recruitment of osteoblast precursors to the site of resorption. For instance, non-resorbing osteoclasts produce afamin which functions as a chemokine to promote pre-osteoblast migration through the activation of the protein kinase B (Akt)-signalling pathway . Afamin small interfering RNA (siRNA)-transfected osteoclasts demonstrated significantly suppressed afamin-stimulated migration of pre-osteoblasts , which could lead to a delayed coupling effect. These results indicate that osteoclasts themselves play a central role in the coupling of bone resorption and formation.
The recruitment of osteoblast precursor cells to osteoclast resorption sites is an important step in the coupling cycle which could occur both in the initiation and reversal phases.
Interestingly, osteoclast-derived sphingosine-1-phosphate (S1P) was found to promote osteoblast precursor recruitment and osteoblast cell survival (Ryu et al., 2006; Pederson et al., 2008; Quint et al., 2013) . On the other hand, S1P antagonists have been shown to reduce osteoclast conditioned media-induced mesenchymal stem cell (MSC) chemokinesis and nodule formation (Pederson et al., BMP6, bone morphogenetic protein 6; CTHRC1, collagen triple helix repeat-containing protein 1; CXCL16, C-X-C motif chemokine 16; HTRA1, high-temperature requirement A serine peptidase 1; IGF, insulin-like growth factor; PDGF, platelet-derived growth factor; PDGF-BB, platelet-derived growth factor subunit B; TGF-ß, transforming growth factor beta; Wnt10b, protein Wnt-10b.
2008). S1P also binds to S1PR1 and S1PR2 receptors to activate the janus kinase (JAK)/signal transducer and activator of transcription (STAT3) and focal adhesion kinase (FAK)/phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT signalling pathways, respectively (Ryu et al., 2006; Quint et al., 2013) . However, recent studies have found that high S1P concentrations are significantly associated with low bone mineral density in postmenopausal women, indicating that the net effect of S1P may be primarily on promoting bone-resorption activities, resulting in bone loss . Consistent with these findings, the addition of S1P to bone marrow monocyte/osteoblast co-cultures enhanced osteoclastogenesis by increasing the expression of RANKL in osteoblasts, providing further evidence that S1P has a regulatory effect on osteoclast precursors, dynamically regulating bone mineral homeostasis (Ryu et al., 2006) . In addition, mature osteoclasts also produce secreted factors protein wnt-10b (Wnt10b) and bone morphogenetic protein (BMP-6) that have an impact on the osteoblastic lineage (Pederson et al., 2008) . Using the Wnt antagonist dickkopf-related protein 1 (DKK-1) and BMP-6-neutralizing antibody, it was found that inhibition of Wnt and BMP-6 reduced osteoclast conditioned media-mediated MSC nodule formation. BMP-6 antibodies have also been shown to reduce osteoclast conditioned media-induced MSC chemokinesis (Pederson et al., 2008) . BMP-6 acts on the specific type-I and type-II serine/threonine kinase receptors BMPR-I and BMPR-II in osteoblast-lineage cells (Pederson et al., 2008) and osteoclast-derived Wnt10b with Frizzled receptors and their co-receptors, low-density lipoprotein receptor-related protein 5 (LRP-5) or LRP-6 in the osteoblast lineage (Ota et al., 2013a) to initiate their effects. Similarly, osteoclast conditioned media also contains complement factor 3a (C3a) that acts on the C3a receptor (C3aR) (Matsuoka et al., 2014) to promote bone formation in the BMU. Treatment with the C3aR antagonist SB290157 results in the attenuation of bone formation and the exacerbation of bone loss in ovariectomized (OVX) rats (Matsuoka et al., 2014) , suggesting a positive influence of osteoclast-derived C3a on osteoblastogenesis. Conversely, the C3aR agonist benzeneacetamide increases osteoblast differentiation and therefore bone formation (Matsuoka et al., 2014) . Cardiotrophin-1 (CT-1) is expressed in osteoclasts and binds with glycoprotein 130 (gp130) receptors in osteoblasts, enhancing osteoblast activity and mineralization (Walker et al., 2008) . In vivo analysis revealed that CT-1 (−/−) neonate mice demonstrated low bone mass associated with reduced osteoblast numbers despite the presence of many large osteoclasts, suggesting that CT-1 is required for the coupling effect promoting osteoblast activity (Walker et al., 2008; Sims & Walsh, 2010 ). All the above-mentioned osteoclast-derived factors are expressed in osteoclasts independent of bone resorption activity. By contrast, collagen triple helix repeat-containing protein 1 (CTHRC1) is only expressed in osteoclasts undergoing bone resorption (Takeshita et al., 2013) . CTHRC1 is secreted by mature bone-resorbing osteoclasts, and binds to the wnt-frizzled (Wnt-Fzd)/neurotrophic tyrosine kinase, receptor-related 2 (Ror2) receptor complex of stromal cells to stimulate osteogenesis (Yamamoto et al., 2008; Takeshita et al., 2013) . Overall, these osteoclast-secreted factors are likely produced at different time points to assist in the regulation of coupling of bone resorption and formation in a phase-specific manner. While all of the above osteoclast-secreted factors positively influence osteoblast activities, the serine protease high-temperature requirement A serine peptidase 1 (HTRA1) is a secreted factor released by osteoclasts which inhibits osteoblast differentiation , suggesting that osteoclasts have the ability to produce both negative and positive factors to modulate a fine balance of the bone remodelling process.
(2) Matrix-derived factors released during osteoclastic bone resorption Matrix-derived factors are totally dependent on osteoclastmediated bone resorption activities, since these factors are embedded in the bone matrix during its formation, and reactivated during the next cycle of osteoclastic bone resorption to promote osteoblast activities (Oreffo et al., 1989) (Fig. 3B) . Howard et al. (1981) first proposed that resorption was accompanied by the release of growth factors stored in the bone matrix which contribute to the restoration of bone loss and coupling activities within the BMU. To date, a number of matrix-derived factors have been identified, including TGF-ß (Bonewald & Mundy, 1990; Crane & Cao, 2014) , BMP-2 (Fuller et al., 2008) , platelet-derived growth factor (PDGF) (Sims & Martin, 2015) , and insulin-like growth factors (IGFs) (Mohan & Baylink, 1996) , which are also activated by plasmin generated by plasminogen activators (Campbell et al., 1992; Yee et al., 1993) and matrix-metalloproteinases (Dallas et al., 2002) . In mouse genetic experiments, TGF-ß1 was found to promote the migration of MSCs in the bone microenvironment and facilitated the coupling of bone resorption with formation (Tang et al., 2009) . Further, matrix-released TGF-ß1 can induce Wnt10b production in osteoclasts to induce osteogenesis (Ota et al., 2013a) , and C-X-C motif chemokine 16 (CXCL16) and leukaemia inhibitory factor (LIF) to modulate recruitment of osteoblasts during bone remodelling (Ota et al., 2013b) . IGF-1 released from matrix was also found to promote osteoblast differentiation by favouring recruitment of MSCs (Xian et al., 2012) . In the bone microenvironment, dysregulation of these matrix-released factors can contribute to the progression of certain disease processes. For example, dysregulation of TGF-ß alters the fate of MSCs (Crane & Cao, 2014) , which might affect the remission of typical articular cartilage damage characterized in rheumatoid arthritis (Zheng et al., 2008; Liu et al., 2010) . In bone metastasis, TGF-ß can contribute to the vicious circle of bone metastasis and bone loss (Juarez & Guise, 2011) . Likewise, the development of breast cancer-induced osteolysis secondary to increased bone turnover, can be altered by inhibition of IGF-1 receptor tyrosine kinase activity (Logan et al., 2013) .
It has been found that inhibition of bone resorption function without affecting osteoclast differentiation by Odanacatib (ODN), a selective and reversible inhibitor of cathepsin K, does not cause a reduction in bone formation. In fact, it was found that bone formation was actually preserved at certain skeletal sites (Sims & Ng, 2014 ). It appears that ODN prevents the degradation of matrix-derived proteins in supernatants of osteoclasts, including IGF-1, and BMP-2 (Fuller et al., 2008) . This preservation of bone formation appears to be due to the effects of coupling factors secreted by osteoclasts and released from demineralized bone matrix. In comparison, inhibition of both osteoclast formation and bone resorption by long-term bisphosphonate use is linked to the occurrence of osteonecrosis of the jaw (ONJ) (Reyes et al., 2016) or atypical sub-trochanteric femoral fractures (Miller & McCarthy, 2015) due to its adverse effects on bone remodelling, resulting in decreased bone formation. Similarly, complete inhibition of both osteoclast formation and bone resorption by Denosumab, a humanized anti-RANKL antibody, leads to a reduction in bone formation due to reduced osteoblast activity secondary to the loss of osteoclast-derived coupling factors that serve to stimulate bone formation (Kostenuik et al., 2009) . These results indicate that matrix-derived factors released by osteoclasts during bone resorption are separable from osteoclast-derived factors in the regulation of coupling activities in time and space.
Osteoclasts undergo apoptosis at reversal sites in the BMU where new bone is laid down by osteoblasts. It remains to be seen whether osteoclasts produce specific coupling factors during this apoptotic or autophagic stage to further facilitate a transition from bone resorption to bone formation. Identification of these putative coupling factors will be an interesting future direction.
(3) Osteoclast membrane-bound factors: a juxtacrine mechanism
In addition to osteoclast-secreted and matrix-derived soluble coupling factors, recent studies indicate that osteoclasts and their precursors can regulate osteoblast formation and function by means of direct cell-to-cell contact via cell-surface regulatory proteins (Fig. 3C ). EphrinB2 protein expressed by osteoclasts as a cell surface molecule can interact with its receptor EphB4 in osteoblasts to regulate osteoblast differentiation, and the EphB4 receptor can signal to EphrinB2 in the reverse direction to suppress the formation of osteoclast precursors (Zhao et al., 2006) . Bidirectional signalling between the cell-surface ligand EphrinB2 and its receptor EphB4 demonstrates the coupling of osteoblastogenesis, osteoclastogenesis, and angiogenesis, and therefore the regulation of bone resorption and remodelling. The EphrinB2/EphB4 axis is dysregulated in multiple myeloma, and its activation by EphB4-Fc inhibits myeloma growth and bone disease (Pennisi et al., 2009) .
Semaphorin 4D (Sema-4D) is another product of osteoclasts that has been identified to act through its receptor Plexin-B1 on osteoblasts to inhibit its function, tipping the balance of bone homeostasis in favour of resorption (Negishi-Koga et al., 2011) . Antibody treatment specific to Sema-4D markedly prevented bone loss in a model of postmenopausal osteoporosis (Negishi-Koga et al., 2011) , and its inhibition partly counteracts alveolar bone loss caused by osteoporosis and lytic skeletal metastases associated with breast cancers and other epithelial malignancies which overexpress Sema-4D . This is significant because treatments directed at suppression of skeletal metastases usually work by arresting bone remodelling, potentially leading to skeletal fragility. Targeting Sema-4D in these cancers may therefore elicit an improved therapeutic result without the debilitating side effects.
(4) Osteoclast-derived exosomal packaging microRNA
Osteoclast-derived exosomal microRNAs (miRNAs) represents a new class of osteoclast-released coupling factor. miRNAs are small non-coding RNA molecules containing ∼22 nucleotides that regulate gene expression to coordinate a broad range of biological processes (Rigoutsos & Furnari, 2010) . A series of miRNAs has been characterized that regulate osteoblastic bone formation, and the dysregulation of these miRNAs has been linked with skeletal disorders characterised by a reduction in bone formation (Fig. 3D) . Exosomal-containing miR-214-3p Sun et al., 2016) is an osteoclast-derived inhibitor of osteoblast differentiation and bone formation. Increased osteoclastic miR-214-3p is associated with both elevated serum exosomal miR-214-3p and reduced bone formation in elderly women with fractures and in ovariectomized mice . In vitro and in vivo studies showed that osteoclast-derived exosomal miR-214-3p can negatively impact osteoblastic bone formation, suggesting a model of miRNA-mediated osteoclast-to-osteoblast communication serving to maintain homeostasis of the local bone environment Sun et al., 2016) . Osteoclast-derived exosomal miR-214 is transferred to osteoblasts to inhibit their activity via targeting EphrinA2/EphA2 (Sun et al., 2016) and activating transcription factor 4 (ATF4) . In addition, miR-214 also plays a critical role in osteoclast differentiation via an autocrine effect . miR-214 promotes osteoclastogenesis of bone marrow-derived macrophage (BMM) cells through the PI3K/Akt pathway, and the inhibition of miR-214 to impede osteoclastogenesis . Therefore, miR-214-containing exosomes from osteoclasts may have multiple effects that could lead to the inhibition of osteoblasts and stimulation of osteoclast activity. Clinically, therapeutic inhibition of miR-214-3p may be a potential bone anabolic strategy to reverse established osteoporosis.
To date, there is only one osteoclast-derived exosomal-containing miR-214-3p which has been identified to have a role in the regulation of osteoblast activity, adding to the coupling effect. It remains to be explored, but it is also likely that pre-osteoclasts may also produce exosomal-containing miRNAs that regulate osteoblast activity. Multiple lines of evidence show that exosomal-containing miRNAs are produced by osteoblast lineage cells and regulate osteoclast activity via a paracrine mechanism, independent from coupling effects. For example, osteoblast-derived exosomal miR-503-3p has been shown to inhibit RANK expression and RANKL-induced osteoclast differentiation . Furthermore, knockdown and overexpression of miR-503 promoted and inhibited bone resorption in OVX mice, respectively . Human bone marrow-derived mesenchymal stem cell (HBMSC)-derived exosomal miR-148a has also been shown to suppress V-maf musculoaponeurotic fibrosarcoma oncogene homolog B (MAFB) expression and promote osteoclastogenesis (Cheng et al., 2013) .
There is growing evidence that exosomal-containing miRNAs are produced from osteoblast lineage cells to regulate osteoblast activities via an autocrine mode of action. For example, lethal-7 (Let-7) has been identified in exosomes from both osteoblast precursors and mineralized osteoblasts, and promotes osteogenesis by regulating high-mobility group AT-hook 2 (HMGA2) . In-vitro culture demonstrated that exosomal miRNAs (including miR-30d-5p, miR-133b-3p miR-140-3p, miR-335-3p, miR-378b and miR-677-3p) were up-regulated in mineralizing MC3T3-E1 cells (Cui et al., 2016) . Functional studies showed that miR-30d-5p and miR-133b-3p target the runt-related transcription factor 2 (RUNX2) gene and inhibit osteoblast differentiation Y. Zhang et al., 2011a) , and miR-140-3p inhibits BMP-2 expression and osteoblast formation (Schaap-Oziemlak et al., 2010) . miR-335-5p down-regulates the Wnt antagonist DKK-1 and promotes osteogenic differentiation (J. Zhang et al., 2011b) . miR-378 regulates the PI3K/Akt signalling pathway and glucose-mediated osteogenic differentiation (You et al., 2014) . miR-677-3p was found to regulate axis inhibition protein 1 (AXIN1) and enhance MSC osteogenic differentiation (Cui et al., 2016) . Using isolated HBMSC exosomes, a number of miRNAs (miR-199b, miR-218, miR-148a, miR-135b, and miR-221) were identified to be up-regulated during HBMSC culture, whilst a separate set of miRNAs (miR-155, miR-181a, miR-221, miR-320c and miR-885-5p) were shown to be down-regulated . Mechanistic studies revealed that miR-199b regulates RUNX2 and osteoblast differentiation (Lauvrak et al., 2013) , and miR-135b reduced the expression of integrin binding sialoprotein (IBSP) and Osterix, as well as affecting mineralization during osteogenic differentiation (Schaap-Oziemlak et al., 2010) . miR-221 and miR-885-5p repressed RUNX2 and impaired osteogenic differentiation . miR-218 stimulates the Wnt pathway by down-regulating three Wnt signalling inhibitors, thus promoting osteoblast differentiation and activity . miR-181a represses TGF-ß signalling molecules by targeting the negative regulator of osteoblastic differentiation Tgf-ß induced (Tgfßi) and TßR-I/Alk5 (TGF-ß type I receptor) and promotes osteoblastic differentiation (Bhushan et al., 2013) . miR-196a has been found to be upregulated during differentiation of osteogenic mesenchymal stem cells derived from human adipose tissues (hASCs), and target homeobox protein Hox-C8 (HOXC8) to promote hASCs osteogenic differentiation (Kim et al., 2009) . Collectively, these osteoblast-derived exosomal miRNAs regulate osteoblast differentiation and bone remodelling by targeting key osteoblast signalling molecules. Table 2 lists bone cell-derived exosomal miRNAs that have been shown to have a potential role in the regulation of bone formation and remodelling.
IV. OTHER LOCAL FACTORS THAT AFFECT BONE REMODELLING
Osteogenesis during bone remodelling is coupled with angiogenesis for nutrient supply, assisting further coupling of bone resorption and bone formation (Figs 1 and 2) . Platelet-derived-growth-factor-BB (PDGF-BB) secreted by pre-osteoclasts stimulates proliferation and migration of both endothelial progenitor cells (EPCs) and MSCs, and promotes CD31 and endomucin [CD31(hi)Emcn(hi)]-induced vessel formation during bone remodelling, thus coupling angiogenesis and osteogenesis . PDGF-BB secreted by pre-osteoclasts influences spatial and temporal regulation of blood vessel formation during new bone formation, and is believed to have further roles including: the mobilization of cells of mesenchymal origin, the stabilization of newly formed vessels, and orchestrating cellular Xu et al. (2014) components for osteoblast differentiation Xie et al., 2014) . Other secreted factors including adipogenic signalling molecules (such as leptin and adiponectin) have effects on the bone microenvironment by the modulation of bone marrow adipocytes, leading to impaired angiogenesis and osteogenesis (Muruganandan & Sinal, 2014) . The angiocrine factor Noggin mediates the endothelialcell-specific Notch pathway and osteogenesis Ramasamy et al., 2014) . Further, Notch signalling in endothelial cells can regulate haematopoietic stem cell niches via CD31-positive capillaries and PDGFR-B-positive perivascular cells (Kusumbe et al., 2016) . Epidermal growth factor-like domain 7 (EGFL7) which is expressed in osteoclasts and osteoblasts is an antagonist to the Notch pathway (Schmidt et al., 2009) , and regulates endothelial cell migration and angiogenesis (Chim et al., 2013 (Chim et al., , 2015 . In addition, EGFL6, Nephronectin (NPNT) and Cxcl9 are expressed by osteoblasts to regulate angiogenesis via a paracrine mechanism in the bone microenvironment (Chim et al., 2011; Huang et al., 2016; Kuek et al., 2016) . Interestingly, NPNT and CD31 expression is reduced in the bone of ovariectomised mice and patients with osteoporosis . It is likely that exosomal-containing miRNA released from osteoclasts and osteoblasts could also regulate angiogenesis in the bone microenvironment. Identification of novel angiogenic and angiocrine factors that regulate trabecular bone mass and angiogenesis in the bone microenvironment should be a future subject of investigation.
Recently, neural factors have been implicated in having an equally important role in the coupling activities of the bone microenvironment. For instance, the exon guidance molecule Sema-3A is expressed by osteoblasts and binds to its receptors neuropilin 1 (Nrp-1) and Nrp-2 expressed in osteoclasts and osteoblasts to regulate bone remodelling (Hayashi et al., 2012; Verlinden et al., 2013) . Sema-3a−/− mice developed an osteopenia phenotype due to increased osteoclast activity and decreased osteoblast activity (Hayashi et al., 2012) . Sema-4D expressed by osteoclasts binds to its receptor Plexin-B1 (Plxn-b1) on osteoblasts to supress osteoblast activity and motility, resulting in an osteosclerotic phenotype with increased bone formation in Sema-4d−/− mice/Plxn-b1−/− mice (Negishi-Koga et al., 2011) . In a rat tibial growth plate injury model, the gene expression of neurotrophins beta-nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and NT-4 and their tropomyosin receptor kinase (Trk) receptors was increased within the site of injury (Su et al., 2016) . Remarkably, recombinant NT-3 was able to enhance osteogenic repair with increased gene expression of BMP-2, VEGF, and the endothelial cell marker CD31 (Su et al., 2016) (Fig. 2) . However, different neural factors and their corresponding receptors are commonly co-expressed in cells of the BMU, creating a complex network of coupling activity. Further studies are required to elucidate the role of these neural factors in the regulation of bone remodelling via multiple cell-communication mechanisms within the BMU.
V. CONCLUSIONS
(1) Bone is a dynamic tissue that undergoes life-long remodelling regulated by the tight coupling of bone resorption and bone formation.
(2) During bone remodelling, osteoclast bone resorption and osteoblast bone formation are coupled to maintain control of skeletal mass.
(3) Osteoclast-derived factors and exosomal-packaged miRNAs can either be inhibitory or stimulatory to promote osteogenesis, and emerging evidence indicates that osteoclasts regulate osteoblast bone formation independent of its resorptive activity.
(4) Osteogenesis in bone remodelling is coupled with angiogenesis. Factors released by pre-osteoclasts and osteoclasts are able to coordinate angiogenesis temporally and spatially during bone growth and remodelling.
(5) It is remarkable that given that so many contributors are involved in the coupling process, a genetic error of a single participant can lead to a pathology involving altered bone remodelling, when it might be reasonable to expect that compensatory mechanisms would normalise the balance in the BMU.
(6) The pathways involved in bone remodelling are far more complex than our current understanding, and new insights into the mechanisms of coupling will assist in the translation of these factors into novel therapeutic approaches for the treatment of bone diseases.
(7) Much work remains to be done to understand fully the nature and significance of the individual factors involved in coupling, the interplay between the many contributors, the time-and dose-specific effects of each factor, and their regulation during bone growth and pathology.
